Nib Holdings Limited Overview
nib is Australia's fourth/fifth-largest private health insurer by market share and a leading trans-Tasman health funder, covering 1.95 million people across Australia and New Zealand at 30 June 2026. Its core is the Australian Residents Health Insurance (arhi) business — a digitally led, multi-channel insurer that has consistently grown above system through brokers, comparison sites, white-label partners and its own brand. Around this core nib has built "adjacent" businesses: International health insurance for students and temporary workers (including the Pacific Australia Labour Mobility scheme), nib New Zealand, NDIS plan management (nib Thrive) and nib Health Services (Honeysuckle Health, Midnight Health, ItsMyGroup). In FY26 it completed its exit from travel insurance, sharpening its identity as a pure-play health insurance and health services group. Its strategic thesis — moving from "payer to partner" — is to use data, AI, provider networks and health management programs to lower costs and improve outcomes, defending margins in a regulated, inflationary industry.
Company's own description
In its interim report, nib describes the Group's principal activities as being a private health insurer in Australia and New Zealand, underwriting and distributing private health insurance to residents and to international students, workers and visitors, alongside complementary health and disability-related services (2026 Interim Report, Directors' Report). The FY26 results announcement frames the mission as helping customers "access and navigate healthcare with confidence", with a stated forward focus on customer value, affordability, access to care, sustainable growth, provider partnerships, care navigation, and the use of technology, data and AI (FY26 ASX Announcement, CEO statement).
Independent characterisation
nib is fundamentally a short-tail, community-rated health insurance underwriter whose earnings are driven by (i) policyholder growth, (ii) the annual government-approved premium increase (5.47% effective 1 April 2026), (iii) claims inflation and utilisation, (iv) risk equalisation transfers in the Australian community-rated system, (v) operating expense efficiency, and (vi) investment returns on regulatory capital and float. Around 78% of FY26 insurance revenue came from the Australian residents business ($3,012.7m of $3,685.7m Group insurance revenue — FY26 ASX Announcement).
Revenue model mix (FY26)
| Revenue type | FY26 (AUD Mn) | Share of total income (%) | Nature |
|---|---|---|---|
| Insurance revenue (all insurance segments) | 3,685.7 | 95.6 | Premium-based, annual/monthly policies (subscription-like recurring revenue) |
| Other income | 169.1 | 4.4 | Fees (NDIS plan management fees at nib Thrive $55.0m), health services operating income ($25.4m), distribution commissions, other |
| Total income | 3,854.8 | 100.0 | — |
Source: FY26 ASX Announcement, Group financial performance table. Net investment income ($57.0m) is reported below operating profit and is excluded from "total income" above.
Value-chain position
nib sits at the funder/payer layer of the health value chain: it collects premiums, pays benefits to hospitals, medical specialists and extras providers (dental, optical, physio, audiology, mental health), and increasingly contracts with providers (multi-year hospital agreements covering >80% of hospital spend per 1H26 webcast; "First Choice" preferred-provider network; Known Gap/No Gap specialist arrangements). Through Health Services it moves into care navigation and delivery (telehealth, virtual health management programs via Honeysuckle Health, Midnight Health) and distribution technology (ItsMyGroup platform supporting 18 PHI brands and facilitating >10% of industry PHI sales — FY26 ASX Announcement).
Customer types and end-markets
| Customer type | Segment | End-market |
|---|---|---|
| Australian resident individuals, couples, families | arhi | Australian private health insurance (hospital + extras) |
| International students (OSHC), temporary graduates, skilled workers, PALM scheme workers | International health insurance | Australian overseas visitor/student health cover; NZ international cover |
| New Zealand residents (individual and corporate/group schemes) | nib New Zealand | NZ private medical, life and living insurance |
| NDIS participants (plan management) | nib Thrive | Australian disability services (NDIS plan management) |
| Insurers, employers, governments (B2B), and nib members | nib Health Services | Health management programs, telehealth, PHI distribution technology |
| White-label partners, brokers, comparison sites | Distribution across segments | Intermediated insurance distribution |
| Travellers (until Sept 2026) | nib Travel (divested) | Travel insurance — now distribution-only via Allianz Partners partnership |
Strategy
Stated strategic themes (FY25–FY26 reporting)
-
Customer-first, digital-led: Over 70% of Australian PHI policies connected digitally (FY25); 86.3% claims automation (FY26).
-
Payer to partner: Shifting from passive funder to active partner in health outcomes — provider partnerships, care navigation, health management programs.
-
Focus on core: Exit from travel to concentrate capital on health insurance and health-adjacent businesses in ANZ.
-
Productivity & performance agenda: $18m savings (FY25); cumulative $39m by 1H26; $61m of value created in FY26.
-
AI and data: 50+ AI/ML initiatives (FY25); nibGPT used by 700+ operational staff; automated call summaries (FY26).
-
Sustainable, high-quality growth: Prioritising Silver-tier, long-tenure customers; reviewing partner/white-label economics alongside brand and direct investment.
Initiatives register (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| CEO transition | Dec 2024 | Ed Close succeeds Mark Fitzgibbon | Complete |
| nib Travel strategic review | May 2025 – Sep 2026 | Review and sale of all travel businesses | Complete |
| NZ recovery plan | FY25–FY26 | Repricing, product changes, benefits management | UOP restored to $27.5m |
| Productivity, digital & AI agenda | FY24 onwards | Simplification, automation, AI deployment | $61m value FY26 |
| Long-term hospital agreements | FY25–FY26 | Multi-year contracts covering >80% of hospital spend | Ongoing |
| First Choice network expansion | FY26 | Added audiology and mental health providers | Ongoing |
| Health management programs | FY25–FY26 | 22,300+ customers participated (FY26); 93% delivered virtually (1H26) | Scaling |
| Allianz Partners distribution partnership | Jun 2026 | Long-term distribution of nib-branded travel insurance (commission-based) | Commenced Sept 2026 |
| Capital management | Aug 2026 | Payout ratio raised to 65–75%; 5c special dividend; further optionality from Travel proceeds | Active |
Medium-term targets / guidance (FY27)
-
Group UOP $265m–$285m excl. nib Travel, subject to risk equalisation (vs FY26 UOP excl. Travel of $256.1m).
-
Significantly lower one-off costs; further improvement in Group operating expense ratio.
-
arhi: sustainable high-quality policyholder growth; underlying net margin 6–7%; broadly stable gross margin.
-
International and NZ: ongoing strong contributions; Health & Insurance Services: positive UOP growth.
-
Dividend payout ratio target 65–75% of NPAT.
Source: FY26 ASX Announcement, FY27 Outlook.
Products & Services
Australian Residents Health Insurance
| Product / brand | Description | Target customer | Pricing model | Notes |
|---|---|---|---|---|
| nib Hospital covers — Gold | Comprehensive hospital cover across all clinical categories required under the PHI tier system | Families, older customers, those planning major treatment | Community-rated annual premium, varies by state/excess | Tiering per 2019 federal reforms |
| nib Hospital covers — Silver (incl. Silver Plus) | Mid-tier hospital covers; strategic target category | Young families, value-seeking customers | Premium + excess | 85% of FY26 net growth came through Silver vs 46% in FY25 (FY26 webcast) |
| nib Hospital covers — Bronze / Basic | Entry-level hospital covers, often purchased to avoid Medicare Levy Surcharge | Younger singles, tax-motivated buyers | Lower premiums, higher excess | Deliberately de-emphasised in FY26 portfolio mix |
| nib Extras covers | Dental, optical, physiotherapy, chiropractic, audiology, mental health and other ancillary benefits | Broad | Annual limits per category | First Choice network delivers no/low gap |
| Combined packages | Bundled hospital + extras | Families | Bundled premium | — |
| First Choice provider network | Preferred dental, optical, audiology and mental health provider network | All extras holders | Negotiated provider fees | Saved customers $57m in out-of-pocket costs in FY26 |
| Known Gap / No Gap specialist arrangements | Pre-agreed specialist gap fees | Hospital members | Contracted | Highlighted in FY25 presentation |
| White-label PHI | nib-underwritten products sold under partner brands | Partner customer bases | Partner distribution fees | Partner economics under review in FY26 |
| Digital channels (nib app, online claims) | Digital servicing; 86.3% of claims automated, 94.8% processed within 24 hours (FY26) | All | — | NPS +32 |
International Health Insurance
| Product | Description | Target customer | Notes |
|---|---|---|---|
| Overseas Student Health Cover (OSHC) | Visa-compliant cover for international students | Student visa holders | Demand linked to student visa caps/policy |
| Overseas Visitors / Workers Health Cover | Cover meeting visa condition 8501 for temporary workers | Skilled workers, temporary graduates | Growth driver in FY26 |
| PALM scheme cover | Health cover for Pacific Australia Labour Mobility workers | Pacific/Timor-Leste seasonal and long-term workers | Policyholder growth driver in FY26 |
| NZ international cover | Cover for international workers/students in NZ | NZ visa holders | — |
FY26: insurance revenue $236.9m (+7.4%), UOP $35.1m (+15.1%), policyholder growth 4.4%, NPS +62 (FY26 ASX Announcement).
nib New Zealand
| Product | Description | Notes |
|---|---|---|
| Individual health insurance | Surgical, hospital and everyday covers | Repriced in FY25–FY26 to restore profitability |
| Corporate/group health schemes | Employer-sponsored health plans | — |
| Life & living insurance | Life cover, trauma, income protection | — |
| Benefits management | Utilisation management initiatives | Utilisation inflation cut to 4% from 10% in 1H26 |
FY26: insurance revenue $429.4m (+7.0%), UOP $27.5m (FY25: −$2.9m), claims inflation moderating to 12%, NPS +2 (1H26) to +25 (2H26).
nib Thrive
| Service | Description | Notes |
|---|---|---|
| NDIS plan management | Financial administration of NDIS plans: invoice processing, provider payment, budget tracking | 40,000+ participants supported in FY26; 42,070 at 31 Dec 2025 (down 6.9%), with positive growth returning in Jan 2026 |
| Participant support / digital tools | Portal/app for budget tracking | Investment in service capability and technology during sector reform |
FY25: processed 3.4m claims worth $2.5bn (FY25 announcement). FY26: fee income $55.0m, UOP $16.3m.
nib Health Services
| Brand | Description | Key metrics | Ownership notes |
|---|---|---|---|
| Honeysuckle Health | Health data analytics and virtual health management programs (chronic disease, pre/post-operative, weight/metabolic) sold to nib and external clients | 18,500+ program enrolments (FY26); external client satisfaction +91.3 | Originally JV with Cigna; current ownership structure to be verified in 2026 Annual Report |
| Midnight Health | Telehealth / digital health platform (direct-to-consumer treatments) | Part of >150,000 telehealth consultations facilitated across the Group in FY26 | Partnership/ownership interest led by Ed Close pre-2024 |
| ItsMyGroup | PHI distribution and technology platform (comparison/advice, AI-enabled sales capabilities) | Supports 18 PHI brands; facilitates >10% of industry PHI sales | — |
FY25: Honeysuckle Health and Midnight Health combined gross revenue $70.2m (+51.6%) (FY25 announcement). FY26: segment operating income $25.4m (+46.0%), UOP $2.4m.
nib Travel (divested)
| Brand | Description | Disposition |
|---|---|---|
| World Nomads | Global adventure travel insurance brand | Sold to International Medical Group (SiriusPoint) for $67.5m; completed 30 Sep 2026 |
| Travel Insurance Direct (TID) | Direct online travel insurance (AU/NZ) | Sold to Allianz Partners; completed 17 Sep 2026 |
| nib Travel (incl. partnerships, white label) | nib-branded and partner travel insurance | Underwriting/partnerships sold to Allianz Partners; nib continues to distribute nib-branded travel insurance under a long-term (20-year white-label, per ITIJ) partnership |
Financial Narrative
Income statement
Sources: 2025 Notice of AGM five-year table (revenue FY22–FY25, DPS, payout ratios); FY22 ASX Announcement (UOP $235.3m, NPAT $133.8m); FY23 ASX Announcement (UOP $263.2m, NPAT $191.8m per Insurance Business reporting of announcement, revenue $3.1bn); FY25 ASX Announcement (UOP FY24 $257.5m, FY25 $239.2m, NPAT FY24 $181.6m, FY25 $198.6m, EPS 41.1c); FY26 ASX Announcement (all FY26 and restated FY25 P&L lines). FY26 revenue shown is "total income" ($3,854.8m) per the FY26 financial table; company headline "Group revenue $3.8 billion, +6.2%".
Data conflicts flagged:
-
FY26 basic EPS of 38.3c is derived (NPAT $186.9m ÷ ~487.7m shares) — verify against Appendix 4E.
-
FY22–FY23 are AASB 1023 basis; the 2025 Notice of AGM five-year table (AASB 17 restated where applicable) contains NPAT values (e.g., 108.5 and 205.7) that do not reconcile to originally reported FY22/FY23 NPAT; the originally reported figures are used above. Payout ratios (74.4% FY22, 68.7% FY23) imply EPS consistent with the originally reported NPAT.
-
FY23 UOP of $263.2m was reported under AASB 1023; the AASB 17-restated FY23 comparative used in FY24 reporting may differ.
Margins and growth
Calculated from 6.1. Revenue CAGR FY22–FY26: ~8.4% p.a. (2,788.6 → 3,854.8; note FY26 definition is total income). Company-reported growth rates differ slightly (FY23 +10.9%, FY25 +7.8%, FY26 +6.2%) due to definitional changes and restatements.
Gross profit / EBITDA: Not reported by nib. As an insurer, nib reports insurance service result, UOP and statutory operating profit rather than gross profit or EBITDA; these are marked not publicly disclosed.
Balance sheet
Sources: InvestSMART financial summary (equity FY23–FY25); FY26 ASX Announcement (debt, gearing, leverage); FY26 Investor Presentation (PCA ratio 1.65x).
Commentary: Debt fell by $71.8m in FY26 to $204.8m, gearing improved 490bps to 15.2%, and leverage reached 0.6x — the strongest balance-sheet position in recent years. The prudential capital ratio (PCA coverage 1.65x for nib health funds) sits comfortably above typical internal targets. Travel sale proceeds (~$97m net, received in 1H27) will further de-gear or fund capital management.
Cash flow: notes and sources
Sources: FY26 ASX Announcement (net operating cash); InvestSMART (premiums received). Dividends paid in cash: 1H26 interim dividend $63.4m (2026 Interim Report); 2H26 special component ~$24m (FY26 ASX Announcement).
Ratios
Sources: InvestSMART (ROE FY23–FY25); FY26 ASX Announcement. Current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful/not reported for a health insurer; interest coverage can be approximated as statutory operating profit ÷ net finance costs = ~15.1x in FY26 (215.7/14.3) — derived.
Trend commentary
Revenue: Steady 6–10% annual growth driven by policyholder growth and annual premium increases (5.47% from 1 April 2026). Revenue growth has decelerated modestly as nib deliberately traded volume for mix (Silver focus) and as arhi net policyholder growth slowed from 3.2% (FY25) to 1.9% (FY26).
UOP inflection: UOP peaked at $263.2m (FY23, AASB 1023) amid COVID-era claims deferral, dipped to $239.2m in FY25 as arhi margins were guided down toward 6–7% and NZ fell into loss, then recovered to $260.9m in FY26 on NZ turnaround (+$30.4m), International growth and productivity savings ($61m of value created in FY26).
Mix shift: arhi UOP declined two years running (217.8 → 207.8 → 187.9) while adjacent businesses rose from $45.3m (FY25) to $86.1m (FY26) — a material diversification of earnings.
NPAT vs UOP divergence: FY26 NPAT fell 5.9% despite UOP +9.1% because net investment income dropped $22.0m to $57.0m, one-off/M&A costs were $23.7m, amortisation of acquired intangibles rose to $16.7m and the effective tax rate rose.
Expense discipline: Operating expense ratio fell 110bps to 16.6%; arhi non-marketing expense ratio of 5.3% is the lowest since 2007.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Key products / services |
|---|---|---|
Australian Residents Health Insurance (arhi) | nib-branded and white-label private health insurance for Australian residents | Hospital (Gold/Silver/Bronze/Basic tiers), extras, combined covers; First Choice network; Known Gap/No Gap specialist arrangements |
International Health Insurance (formerly iihi) | Cover for international students, temporary graduates, skilled workers, PALM scheme workers in Australia and NZ | Overseas Student Health Cover (OSHC), Overseas Visitor Health Cover (OVHC), worker cover |
nib New Zealand | Private medical insurance plus life and living (risk) insurance for NZ residents and groups | Individual and corporate health plans; life, income, trauma covers |
nib Thrive | NDIS plan management | Plan management, claims processing, participant support |
nib Health Services | Health management, telehealth and PHI services platform | Honeysuckle Health, Midnight Health, ItsMyGroup |
nib Travel (discontinued, sold Sept 2026) | Travel insurance | nib Travel, Travel Insurance Direct (TID), World Nomads |
Segment revenue (AUD Mn)
| Segment revenue (AUD Mn) | FY25 | FY26 |
|---|---|---|
arhi insurance revenue | 2,832.6 | 3,012.7 |
International health insurance revenue | 220.6 | 236.9 |
nib New Zealand insurance revenue | 401.4 | 429.4 |
nib Thrive fee income | 57.1 | 55.0 |
nib Health Services operating income | 17.4 | 25.4 |
Revenue by Segment
| Segment UOP (AUD Mn) | FY24 | FY25 | FY26 |
|---|---|---|---|
arhi | 217.8 | 207.8 | 187.9 |
International health insurance | 24.8 | 30.5 | 35.1 |
nib New Zealand | — | -2.9 | 27.5 |
nib Thrive | — | 16.9 | 16.3 |
nib Health Services | — | -5.9 | 2.4 |
nib Travel (discontinued) | 8.1 | 6.7 | 4.8 |
Group UOP (incl. Travel) | 257.5 | 239.2 | 260.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment (FY26) Overview
| Segment (FY26) | UOP margin on revenue (%) | Revenue YoY (%) | UOP YoY (%) | Share of Group UOP (%) |
|---|---|---|---|---|
arhi | 6.2 | 6.4 | -9.6 | 72.0 |
International | 14.8 | 7.4 | 15.1 | 13.5 |
nib NZ | 6.4 | 7.0 | n.m. (loss to profit) | 10.5 |
nib Thrive | 29.6 (on fee income) | -3.7 | -3.6 | 6.2 |
nib Health Services | 9.4 (on operating income) | 46.0 | n.m. (loss to profit) | 0.9 |
nib Travel | — | — | -28.4 | 1.8 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Group underlying revenue (AUD Mn) | 2,788.6 | 3,051.0 | 3,337.2 | 3,599.2 | 3,854.8 |
Insurance revenue (AUD Mn) | — | — | — | 3,461.4 | 3,685.7 |
Incurred claims (AUD Mn) | — | — | — | 2,740.2 | 2,947.3 |
Total operating expenses (AUD Mn) | — | — | — | 638.2 | 633.7 |
Underlying operating profit UOP (AUD Mn) | 235.3 | 263.2 | 257.5 | 239.2 | 260.9 |
Statutory operating profit (AUD Mn) | — | — | — | 198.7 | 215.7 |
Net investment income (AUD Mn) | — | — | — | 79.0 | 57.0 |
Net finance costs (AUD Mn) | — | — | — | 18.5 | 14.3 |
Profit before tax (AUD Mn) | — | — | — | 259.2 | 258.4 |
Net profit after tax (AUD Mn) | 133.8 | 191.8 | 181.6 | 198.6 | 186.9 |
Basic EPS (A cents) | — | — | — | 41.1 | 38.3 |
Dividend per share incl. special (A cents) | 22.0 | 28.0 | 29.0 | 29.0 | 34.0 |
Ordinary dividend per share (A cents) | 22.0 | 28.0 | 29.0 | 29.0 | 29.0 |
Dividend payout ratio ordinary (%) | 74.4 | 68.7 | 75.7 | 70.6 | — |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
UOP margin on revenue (%) | 8.4 | 8.6 | 7.7 | 6.6 | 6.8 |
NPAT margin on revenue (%) | 4.8 | 6.3 | 5.4 | 5.5 | 4.8 |
Revenue growth YoY (%) | 7.2 | 9.4 | 9.4 | 7.9 | 7.1 |
Operating expense ratio (%) | — | — | — | 17.7 | 16.6 |
arhi hospital benefits payout ratio (%) | — | — | — | — | 88.8 |
Claims inflation arhi (%) | — | — | — | — | 4.1 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Shareholders' equity (AUD Mn) | 980.9 | 1,042.8 | 1,111.1 | — |
Interest-bearing debt (AUD Mn) | — | — | 276.6 | 204.8 |
Gearing ratio (%) | — | — | 20.1 | 15.2 |
Leverage ratio (x) | — | — | 0.8 | 0.6 |
nib health funds PCA coverage (x) | — | — | — | 1.65 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net operating cash flow (AUD Mn) | — | — | — | 165.7 | 199.1 |
Premiums received (AUD Mn) | — | 3,217 | 3,526 | 3,733 | — |
Dividends declared per share (A cents) | 22.0 | 28.0 | 29.0 | 29.0 | 34.0 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Return on equity (%) | 21.1 | 20.8 | 18.1 | — |
Gearing (%) | — | — | 20.1 | 15.2 |
Leverage (x) | — | — | 0.8 | 0.6 |
Operating expense ratio (%) | — | — | 17.7 | 16.6 |
Non-marketing expense ratio arhi (%) | — | — | — | 5.3 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia — residents (arhi) | — | 2,832.6 | 3,012.7 |
Australia/NZ — International health insurance | — | 220.6 | 236.9 |
New Zealand — nib NZ | 371.3 | 401.4 | 429.4 |
Region growth (%)
| Region growth (%) | FY2025 | FY2026 |
|---|---|---|
Australia — arhi revenue growth | 7.3 | 6.4 |
International health insurance revenue growth | 14.4 | 7.4 |
New Zealand revenue growth | 8.1 | 7.0 |
Share Price
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Share price October (AUD) | 6.62 | 6.67 | 7.24 | 5.78 | 7.54 | 6.45 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap (AUD Bn) | ~3.15 | 487.7m shares |
P/E (trailing) | ~16.8x | FY26 EPS 38.3c (derived) |
Dividend yield (trailing, incl. special) | ~5.3% | 34.0c |
Dividend yield (ordinary) | ~4.5% | 29.0c, fully franked |
P/B | ~2.6–2.8x | — |
EV/EBITDA, EV/Sales | Not meaningful for insurer / not computed | — |
Analyst consensus target | A$7.71 | Simply Wall St (Aug 2026) |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim dividend (A cents) | 11.0 | — | — | 13.0 | 13.0 |
Final dividend (A cents) | 11.0 | — | — | 16.0 | 21.0 |
Total dividend (A cents) | 22.0 | 28.0 | 29.0 | 29.0 | 34.0 |
Analyst Conclusions
Management guidance (FY27)
Group UOP $265–285m excl. nib Travel (subject to risk equalisation); lower one-offs; improved OER; arhi net margin 6–7% with broadly stable gross margin; strong International/NZ contributions; positive UOP growth in Health & Insurance Services.
Bull case
-
Earnings diversification is real: Adjacent UOP nearly doubled to $86.1m; NZ swung +$30.4m and International grew 15.1% — reducing dependence on arhi margins.
-
Productivity flywheel: $61m value in FY26, OER down 110bps, and further OER improvement targeted; lower one-offs in FY27 should lift statutory earnings closer to UOP.
-
Capital returns: Higher payout ratio (65–75%), ~5.3% trailing yield and ~$73m of undeployed sale proceeds support shareholder returns, with gearing at only 15.2%.
Bear case
-
Core arhi erosion: arhi UOP has fallen two consecutive years (−9.6% in FY26) and policyholder growth undershot the ~3% target at 1.9%.
-
Earnings quality/volatility: Risk equalisation, rebate/levy adjustments and investment income (−27.8%) make NPAT unpredictable; NPAT declined in FY26 despite UOP growth.
-
Regulatory and cost pressure: Hospital payout ratio 88.8%, political scrutiny of premiums and NDIS reform risk could cap margins.
Catalysts & monitorables (next 12 months)
-
2026 AGM (Oct/Nov 2026) — trading commentary, El-Ansary election.
-
Deployment of remaining Travel proceeds (special dividend, buyback or bolt-on).
-
2027 premium round outcome (announced ~Feb 2027, effective 1 Apr 2027).
-
1H27 results (~Feb 2027): arhi policyholder growth vs target, risk equalisation, NZ margin durability.
-
NDIS plan management reform implementation and Thrive participant trends.
-
Industry claims inflation trajectory vs nib's 4.1%.
Analyst verdict
nib enters FY27 as a simpler, more focused and financially stronger group than at any point in the last five years. The completion of the travel exit in September 2026 removes a cyclical, low-margin business that contributed under 2% of Group UOP, while crystallising roughly $97m of net cash. The FY26 result demonstrated that the "adjacent" strategy is no longer aspirational: International, New Zealand, Thrive and Health Services delivered $86.1m of UOP, about a third of the total, with New Zealand's turnaround and Health Services' first full-year profit particularly important proof points for the new CEO.
The central debate is the core. Australian residents UOP has declined for two years as management deliberately guided margins into the 6–7% band and absorbed rebate, offer-cost and risk-equalisation headwinds. Policyholder growth of 1.9% fell short of the ~3% target, albeit with a better Silver-tier mix. If arhi stabilises — as guidance for broadly stable gross margins implies — nib's lower cost base and moderating own-claims inflation should allow it to compound earnings at mid-to-high single digits, consistent with FY27 guidance of $265–285m.
Against this, the stock has de-rated roughly 15% over the past year to around A$6.45, a trailing P/E of approximately 17x and a fully franked yield above 4.5% on ordinary dividends — undemanding relative to the company's ROE in the high teens and its improved balance sheet. The higher payout ratio and capital optionality provide downside support.
On balance, we view nib as a quality, reasonably valued defensive compounder whose near-term rerating depends on evidence that arhi earnings have troughed and that one-off costs genuinely fall in FY27. The principal risks are regulatory (premium approvals, rebate settings, NDIS reform) and risk-equalisation volatility. Investors should watch the 1H27 result for arhi margin stability and policyholder momentum as the key swing factor.
Derived figures are labelled. It is not investment advice; consult a licensed financial adviser before making investment decisions.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Background |
|---|---|---|---|
Ed Close | Managing Director & CEO | MD & CEO since 1 Dec 2024; joined nib 2017 | Head of Marketing & Products, arhi (2017); CEO arhi (from 2020); led Midnight Health partnership; nib representative on Honeysuckle Health board; prior senior roles at Commonwealth Bank. Total fixed remuneration on appointment: $1,050,000 p.a. (mi-3, 29 Jul 2024) |
Nick Freeman | Group Chief Financial Officer | Current (presented FY26 results) | Details in 2026 Annual Report |
Rob Hennin | CEO, nib New Zealand | Current | Led NZ recovery plan |
Martin Adlington | Chief Executive, nib Thrive | Current | Per InvestSMART management listing |
Jordan French | Company Secretary | Current (authorised 2025–2026 releases) | Succeeded Roslyn Toms |
Troy Frearson | Group Head of Performance, Planning & Investor Relations | Current | — |
Board of Directors
| Name | Role | Status | Notes |
|---|---|---|---|
David Gordon | Independent Non-Executive Chair | Current | Group Chair throughout CEO transition |
Ed Close | Managing Director & CEO | Executive director | — |
Jacqueline Chow | Independent Non-Executive Director | Current | Stepped down from nib NZ board (2023), remains on Group board |
Hisham El-Ansary | Independent Non-Executive Director | Appointed 2 Dec 2025; stands for election at 2026 AGM | Ex-CEO Bupa Asia Pacific; NED RACV; adviser to Goldman Sachs APAC; former Healthscope advisory board |
Donal O'Dwyer | Former NED | Retired 6 Nov 2025 | Joined March 2016; Audit, People & Remuneration, Nominations committees |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Positioning vs nib |
|---|---|---|---|
arhi | Medibank Private (incl. ahm) — ASX: MPL | Listed, for-profit | Market leader (~27% share, APRA approx.); larger scale, also health services |
arhi | Bupa ANZ | Foreign-owned (UK Bupa, mutual-like) | #1/#2 (~25% share approx.); vertically integrated (dental, aged care, optical) |
arhi | HCF | Not-for-profit mutual | ~12% share approx.; strong NSW base |
arhi | HBF | Not-for-profit mutual | ~7% share approx.; dominant in WA |
arhi | Australian Unity / Teachers Health / CBHS / GMHBA / Peoplecare | Mutuals / NFP | Niche and regional; often more price-competitive |
International | Allianz Care, Medibank (OSHC/OVHC), Bupa, ahm OSHC, CBHS International | Mixed | Competitive OSHC/OVHC panel market |
New Zealand | Southern Cross Health Society | NZ not-for-profit | Dominant NZ health insurer (majority share) |
New Zealand | AIA NZ, Partners Life, Accuro, UniMed | Various | nib a strong #2 in NZ health |
NDIS plan management | Plan Partners, My Plan Manager, Leap in!, numerous small providers | Private | nib Thrive among larger, scaled providers |
Health services / distribution | Compare the Market, iSelect, Medibank Health, Bupa health services | Various | ItsMyGroup facilitates >10% of industry PHI sales |
Competitor Detail
| Metric | nib (FY26) |
|---|---|
Group revenue (AUD Bn) | 3.85 |
Revenue growth (%) | 6.2 |
Operating expense ratio (%) | 16.6 |
arhi/resident net margin (%) | 6–7 target |
Recent Developments
--



